Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) Equity Ratio (2019 - 2025)

Historic Equity Ratio for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to 0.74.

  • Beam Therapeutics' Equity Ratio rose 906.64% to 0.74 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.74, marking a year-over-year increase of 906.64%. This contributed to the annual value of 0.66 for FY2024, which is 114.92% down from last year.
  • According to the latest figures from Q3 2025, Beam Therapeutics' Equity Ratio is 0.74, which was up 906.64% from 0.75 recorded in Q2 2025.
  • Beam Therapeutics' Equity Ratio's 5-year high stood at 0.77 during Q1 2025, with a 5-year trough of 0.53 in Q3 2022.
  • For the 5-year period, Beam Therapeutics' Equity Ratio averaged around 0.64, with its median value being 0.61 (2021).
  • Its Equity Ratio has fluctuated over the past 5 years, first plummeted by 2832.35% in 2022, then soared by 2297.65% in 2023.
  • Beam Therapeutics' Equity Ratio (Quarter) stood at 0.56 in 2021, then fell by 2.5% to 0.55 in 2022, then increased by 22.98% to 0.67 in 2023, then decreased by 1.15% to 0.66 in 2024, then increased by 10.87% to 0.74 in 2025.
  • Its Equity Ratio was 0.74 in Q3 2025, compared to 0.75 in Q2 2025 and 0.77 in Q1 2025.